Share on

Global Next Generation Antibody Therapeutics Market Size, Share, Trends, Growth & COVID-19 Impact Analysis Report – Segmented By Therapeutics, Technology & Region - Industry Forecast (2023 to 2028)

Published: March, 2023
ID: 5220
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Next-Generation Antibody Therapeutics Market Size (2023 to 2028)

The size of the global next-generation antibody therapeutics market was worth USD 4.89 billion in 2023 and is expected to grow with a CAGR of 13% to reach USD 9.01 billion by 2028.

Next-generation antibody therapeutics are used to treat various critical medical conditions like cancer, infectious diseases, and immune diseases.

MARKET DRIVERS:

Y-O-Y growth in the prevalence of cancer, technological advancements, and rising geriatric population across the world is expected to drive growth to the global next-generation antibody therapeutics market.

Growing investments from the biopharmaceutical and pharmaceutical companies to develop effective antibodies to treat diseases such as autoimmune, inflammatory, and chronic are expected to fuel the growth rate of the market. The rise in the population aging above 65 years is significantly growing across various parts of the world, which is expected to increase the demand levels for the next generation of antibody therapeutics during the forecast period.

Growing incidence of such as cancer and asthma are further promoting the global next-generation antibody therapeutics market. According to the Asthma and Allergy Foundation of America (AAFA), an estimated 25 million Americans have asthma, which is 1 in 13 Americans. The numbers are increasing year by year. Growing discovery and development activities of monoclonal antibodies is another significant factor boosting the global next-generation antibody therapeutics market.

Furthermore, technological advancements, growing R&D activities, and raising funds and investments from the governments dedicated to the antibody therapeutics sector are propelling the market growth.

MARKET RESTRAINTS:

High costs associated with the antibody’s treatment are one primary factor hampering the next-generation antibody therapeutics market growth.

Complexities associated with the product approvals and strict regulatory forms for manufacturing drugs are expected to restrain the global next-generation antibody therapeutics market growth. Lack of awareness among the patients is further estimated to impedes the market.

Impact of COVID-19 on the global next-generation antibody therapeutics market:

The sudden outburst of novel coronavirus caused by the SARS-CoV-2 originated in China, Wuhan, in December 2019. The virus has caused millions of human infections and deaths. For recovery from this airborne infectious disease, antibody-based therapy treatment is one of the treatment choices. CT-P59 (regdanvimab) a monoclonal antibody to combat coronavirus disease. The antibodies aimed to treat patients with gentle to severe COVID-19 in adults tested positive. Patients treated with CT-P50 present a considerably decreased threat of COVID-19 associated hospitalization and oxygenation without death. Due to the COVID-19, the usage of antibodies has increased, and the market has seen an acceleration in its growth rate. Similarly, the global next-generation antibody therapeutics market is expected to experience significant growth during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2022 to 2028

Base Year

2022

Forecast Period

2023 to 2028

Segments Covered

By Therapeutics, Technology, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

This market research report on the global next-generation antibody therapeutics market has been segmented based on the therapeutics, technology, and region.

Next-Generation Antibody Therapeutics Market – By Therapeutics:

  • Oncology

  • Autoimmune/Inflammatory Diseases

The oncology segment is expected to account for the largest share in the next-generation antibody therapeutics market during the forecast period based on the therapeutics. Cancer accounts for nearly 13% of deaths globally every year, and the mortality rate of cancer is likely to increase at a higher rate in the coming years.

The Autoimmune/Inflammatory diseases segment is predicted to grow at a healthy rate during the forecast period.

Next-Generation Antibody Therapeutics Market – By Technology:

  • Antibody-Drug Conjugates (ADCs)

  • Bispecific Antibodies (BsAbs)

  • Fc Engineered Antibodies

  • Antibody Fragments

  • Antibody-like Proteins

  • Biosimilar Antibody Products

Based on the technology, the antibody-drug conjugates (ADCs) are projected to lead the global next-generation antibody therapeutics market during the forecast period with more than 50% occupancy. The Fc engineered antibodies segment is anticipated to have a healthy CAGR in the global next-generation antibody therapeutics market during the forecast period.

Next-Generation Antibody Therapeutics Market - By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • The Middle East and Africa

Geographically, the North America Next-Generation Antibody Therapeutics Market is was the most dominating regional market globally in 2020 and forecasted to continue the domination throughout the forecast period due to large funds and investments for research and development. Escalation of the elder people population, the growing frequency of chronic diseases is anticipated to boost the market growth in this region. The United States, followed by Canada, is expected to dominate this regional market between 2021 to 2026.

The Europe Next-Generation Antibody Therapeutics Market is estimated to be the second-largest regional market worldwide during the forecast period. Factors such as technological advancements, a growing number of collaborations among the key market participants, developments in the life sciences research infrastructure, growing applications for such therapies, and government support are expected to drive this regional market.

The Asia-Pacific Next-Generation Antibody Therapeutics Market is expected to register with the highest CAGR among all the regions during the forecast period. Growing demand from developing countries such as India and China is a significant growth driver in this regional market. Additionally, the growing incidence of various diseases and rising support from the Asian governments to develop effective therapeutic antibodies favor the market.

The Latin America Next-Generation Antibody Therapeutics Market is projected to grow at a steady rate during the forecast period due to the growing aging population, urbanization, and lifestyle changes.

The MEA Next-Generation Antibody Therapeutics Market is anticipated to grow at a sluggish rate during the forecast period due to the growing occurrence rate of cancer and developments in monoclonal antibody technologies.

KEY MARKET PARTICIPANTS:

Notable companies dominating the global next-generation antibody therapeutics market profiled in the report are Roche, Seattle Genetics, Takeda, Dyax Corp, Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc. and Xencor, Inc.

RECENT MARKET DEVELOPMENTS:

  • In February 2020, Xencor, Inc. received the license to develop the investigational humanized monoclonal antibody XmAb 7195 to Aimmune therapeutics to treat cancer autoimmune diseases.

  • In July 2019, REGENXBIO and Neurimmune AG announced the license, development, and commercialization of agreement to invent and develop new AAV gene therapies using NAV vectors to deliver human antibodies against chronic neurodegenerative diseases, which include tauopathies.

  • In May 2020, Takeda Pharmaceuticals announced the US FDA acceptance of ALUNBRIG for adult patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small lung cancer.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample